Susanne Diehl
Global Vice President, Program Head Immunology Novartis AG
Seminars
Wednesday 3rd December 2025
Panel Discussion: Utilizing Biomarkers to Sustain Durable Responses in Autoimmune Therapies
1:40 pm
- Identifying biomarker differences across indications and modalities
- Harness specific biomarkers to effectively identify patient response, manage patient safety and enhance patient selection
- Explore the use of biomarkers to determine optimal timing for re-dosing and sustaining efficacy
Thursday 4th December 2025
Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies
11:30 am
- Evaluating the autologous and allogeneic cell therapy space
- Identify the optimal approach to maximize therapeutic efficacy
- Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies
- Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalization
